Clinical trial · Observational
Evaluation of Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
Evaluation of Double HER2 Blocking by Pertuzumab-Trastuzumab and Taxane in the Standard Treatment of Metastatic Breast Cancer
NCT03979911CI-TRIAL-00038994EPTTCSMunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective study evaluated the efficacy and the safety of use of this treatment combined with a taxane for the treatment of HER2-positive metastatic breast cancer and compared the clinical and demographic characteristics of real life patients to the patients of CLEOPATRA.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| HER-2 Gene Amplification | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Progression-free survival
- timeFrame
- through study completion, an average of 1 year
- description
- time between inclusion and progression of the disease
- measure
- overall survival
- timeFrame
- through study completion, an average of 1 year
- description
- time between inclusion and death
Secondary outcomes (8)
- measure
- comparison of the age of our population to those of the CLEOPATRA cohort
- timeFrame
- at the inclusion
- description
- % of patients with an age \<65 years and \> 65 years and \<75 years and \> 75 years in our study are compared to those of Cleopatra cohort
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * metastatic breast cancer * HER2 positive * Received pertuzumab in combination with trastuzumab and taxane chemotherapy Exclusion Criteria: * no HER2-positive breast cancer * no association with taxane chemotherapy * no metastatic breast cancer * refusal to consent
References
Publications (0)
Data not yet available
No reference posted for this study.